German Biotech Sector Braces for Landmark Merger Decision

A pivotal moment approaches for Germany’s biotechnology landscape as shareholders of CureVac prepare to vote on November 25 regarding a proposed acquisition by competitor BioNTech. This potential consolidation, valued at €1.25 billion, represents a dramatic shift from what began as intense patent litigation between two pioneering mRNA technology companies.

Under terms initially disclosed in June, CureVac investors would exchange their holdings for BioNTech shares valued at approximately $5.46 per share. Upon transaction completion, former CureVac stakeholders would collectively hold between four and six percent of the combined entity.

BioNTech anticipates the merger will significantly enhance its oncology research capabilities, an area where CureVac maintains valuable mRNA technology assets despite previous COVID-19 vaccine Read more...